Carbopol polymer gel

Drug Profile

Carbopol polymer gel

Alternative Names: BufferGel

Latest Information Update: 04 Dec 2015

Price : $50

At a glance

  • Originator Johns Hopkins University; ReProtect LLC
  • Developer CONRAD; Johns Hopkins University; National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development; ReProtect
  • Class Anti-infectives; Spermicidal contraceptives
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Pregnancy
  • Phase II HIV infections

Most Recent Events

  • 04 Dec 2015 Phase III clinical trials are planned for Contraception and HIV infections (Prevention) in USA
  • 02 May 2001 A clinical study has been added to the adverse events section
  • 29 Mar 2001 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top